CD20 on B Cells
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Evaluation of CD19 deficiency in patients with a suspected CD19 deficiency (humoral immunodeficiency)
Confirming complete absence of B cells in suspected primary humoral immunodeficiencies using both CD19 and CD20 markers
To assess therapeutic B-cell depletion quantitatively (absolute counts of cells/mcL) in any clinical context, including malignancies, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and membranous glomerulonephritis among others, and treatment or prevention of acute humoral rejection in positive crossmatch renal transplant recipients.
This test is not useful for the following applications, instead TAE/82977 Therapeutic Antibody by Flow Cytometry should be ordered in the contexts described below:
-Assessing whether malignant (and nonmalignant) B cells express the target molecule (CD20) of interest in the context of initiating therapeutic monoclonal anti-CD20 antibody therapy (rituximab, ofatumumab, and tositumomab) for any of the hematological malignancies, or in other clinical contexts, such as autoimmunity.
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name